# Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

> Federal funding opportunity · **POSTED** · National Institutes of Health · close: **11/19/2026**

## Key facts

- **Opportunity ID:** 357343
- **Opportunity number:** PAR-25-226
- **Agency:** National Institutes of Health
- **Status:** posted
- **Document type:** synopsis
- **Open date:** 11/22/2024
- **Close date:** 11/19/2026
- **CFDA codes:** 93.242

## Primary source

Grants.gov opportunity detail: https://www.grants.gov/search-results-detail/357343

## Citation

> US Grants.gov, funding opportunity 357343 (PAR-25-226). Retrieved via AI Analytics 2026-05-18 from https://api.ai-analytics.org/opportunity/357343. Licensed CC0.

---

*[Grants.gov dataset](/datasets/grants-gov) · CC0 1.0*